Production (Stage)
Petros Pharmaceuticals, Inc.
PTPI
$0.039
-$0.0084-17.72%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -53.98% | 10.90% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -53.98% | 10.90% | |||
| Cost of Revenue | -7.74% | -12.79% | |||
| Gross Profit | -64.28% | 18.03% | |||
| SG&A Expenses | -37.01% | 0.64% | |||
| Depreciation & Amortization | -11.27% | 3.01% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -36.86% | 5.77% | |||
| Operating Income | 25.33% | -2.58% | |||
| Income Before Tax | -317.59% | -235.45% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -317.59% | -235.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -317.59% | -235.45% | |||
| EBIT | 25.33% | -2.58% | |||
| EBITDA | 31.83% | -2.38% | |||
| EPS Basic | -99.94% | -44.19% | |||
| Normalized Basic EPS | -176.20% | -152.14% | |||
| EPS Diluted | -99.94% | -44.19% | |||
| Normalized Diluted EPS | -176.20% | -152.14% | |||
| Average Basic Shares Outstanding | 2.83% | 33.05% | |||
| Average Diluted Shares Outstanding | 2.83% | 33.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||